Lysine-specific demethylase (LSD1/KDM1A) and MYCN cooperatively repress tumor suppressor genes in neuroblastoma

Oncotarget

Volumn 6, Issue 16, 2015, Pages 14572-14583

  Amente, Stefano ^a   Milazzo, Giorgio ^b   Sorrentino, Maria Cristina ^a   Ambrosio, Susanna ^a   Di Palo, Giacomo ^a   Lania, Luigi ^a   Perini, Giovanni ^b,c   Majello, Barbara ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c CIRI Life Science and Health Technologies/Department of Biology   (Italy)

Author keywords

LSD1; MYCN; Neuroblastoma; Transcription

Indexed keywords

10058 F 4; CLUSTERIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PROTEIN INHIBITOR; PROTEIN P21; RETINOBLASTOMA BINDING PROTEIN 2; TRANYLCYPROMINE; UNCLASSIFIED DRUG; HISTONE DEMETHYLASE; LYSINE; MYCN PROTEIN, HUMAN; N MYC PROTO ONCOGENE PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CDKN1A GENE; CELL PROLIFERATION; CLU GENE; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; GENE FUNCTION; GENE INTERACTION; GENE LOCATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LSD1 GENE; MYCN GENE; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; P21 GENE; PROMOTER REGION; PROTEIN BINDING; TUMOR SUPPRESSOR GENE; CELL DIFFERENTIATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; GENES, TUMOR SUPPRESSOR; HEK293 CELLS; HISTONE DEMETHYLASES; HUMANS; LYSINE; N-MYC PROTO-ONCOGENE PROTEIN; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84931076916     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3990     Document Type: Article

References (43)

1. Huang M and Weiss WA. Neuroblastoma and MYCN. Cold Spring Harbor perspectives in medicine. 2013; 3:a014415.
2. Maris JM, Hogarty MD, Bagatell R, Cohn SL, Neuroblastoma. Lancet. 2007; 269: 2106-2120.
3. Schwab M. MYCN in neuronal tumours. Cancer letters. 2004; 204:179-187.
4. Dang CV, MYC on the path to cancer. Cell. 2012; 149:22-35.
5. Schulte JH, Lindner S, Bohrer A, Maurer J, De Preter K, Lefever S, Heukamp L, Schulte S, Molenaar J, Versteeg R, Thor T, Kunkele A, Vandesompele J, Speleman F, Schorle H, Eggert A, et al. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene. 2013; 32:1059-1065.
6. Brodeur, G. M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer. 2003; 3:203-216.
7. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 1997; 16:2985-2995.
8. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev. 2008; 22:2755-2766.
9. Tu WB, Helander S, Pilstal R, Hickman KA, Lourenco C, Jurisica I, Raught B, Wallner B, Sunnerhagen M and Penn LZ. Myc and its interactors take shape. Biochimica et biophysica acta. 2014.
10. He S, Liu Z, Oh DY, Thiele CJ. MYCN and the epigenome. Frontiers in Oncology. 2013; 3:1.
11. Diolaiti D, McFerrin L, Carroll PA, Eisenmann RN. Functional interactions among members of the MAX and MLX transcription network during oncogenesis. Biochim Biophys Acta 2015; 484-500.
12. Amente S, Lania L and Majello B. Epigenetic reprogramming of Myc target genes. American journal of cancer research. 2011; 1:413-418.
13. Bretones G, Delgado MD, Leon J. Myc and cell cycle control. Biochim Biophys Acta 2015; 505-516.
14. Gherardi S, Valli E, Erriquez D and Perini G. MYCN-mediated transcriptional repression in neuroblastoma: the other side of the coin. Frontiers in oncology. 2013; 3:42.
15. Iraci N, Diolaiti D, Papa A, Porro A, Valli E, Gherardi S, Herold S, Eilers M, Bernardoni R, Della Valle G, Perini G. A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects Neuroblastoma malignancy by inhibiting the cell response to NGF. Cancer Res. 2011; 71:404-412.
16. Jackstadt R, Hermeking H. MicroRNAs as regulators and mediators of c-MYC function. Biochim Biophys Acta. 2015; 5:544-553.
17. Corvetta D, Chayka O, Gherardi S, D'Acunto CW, Cantilena S, Valli E, Piotrowska I, Perini G and Sala A. Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications. The Journal of biological chemistry. 2013; 288:8332-8341.
18. Wang C, Liu Z, Woo CW, Li Z, Wang L, Wei JS, Marquez VE, Bates SE, Jin Q, Khan J, Ge K and Thiele CJ. EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer research. 2012; 72:315-324.
19. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R, Ora, I, Pajtler K, Klein-Jitpass L, Kuhfittig-Kulle S, Metzger E, Schule R, Eggert A, Buettner R, Kirfel J. Lysinespecific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Research. 2009; 69:2065-2071.
20. Shy Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004; 119:941-953.
21. Lan F, Nottke AC and Shi Y. Mechanisms involved in the regulation of histone lysine demethylases. Curr Opin Cell Biol. 2008; 20:316-325.
22. Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, Gunther T, Buettner R, Schule R. LSD1 demethylates repressive histone marks to promote androgen-receptor dependent transcription. Nature. 2005; 437:436-439.
23. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T and Berger SL. p53 is regulated by the lysine demethylase LSD1. Nature. 2007; 449:105-108.
24. Kontaki H and Talianidis I. Lysine methylation regulates E2F1-induced cell death. Molecular cell. 2010; 39:152-160.
25. Wang J, Hevi S, Kurash JK, Lei H, Gay F, Bajko J, Su H, Sun W, Chang H, Xu G, Gaudet F, Li E and Chen T. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nature genetics. 2009; 41:125-129.
26. Shi YJ, Matson C, Lan F, Iwase S, Baba T, Shi Y. Regulation of LSD1 histone demethylase activity by its associated factors. Molecular Cell. 2005; 19:857-64.
27. Klose RJ, Zhang Y. Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol. 2007; 4:307-318.
28. Lynch JT, Harris WJ and Somervaille TC. LSD1 inhibition: a therapeutic strategy in cancer? Expert Opin Ther Targets. 2012; 16:1239-1249.
29. Amente S, Lania L and Majello B. The histone LSD1 demethylase in stemness and cancer transcription programs. Biochimica et biophysica acta. 2013; 1829:981-986.
30. Rotili D and Mai A. Targeting Histone Demethylases: A New Avenue for the Fight against Cancer. Genes Cancer. 2011; 2:663-679.
31. Lim S, Metzger E, Schule R, Kirfel J, Buettner R. Epigenetic regulation of cancer growth by histone demethylases. International Journal of Cancer. 2010; 127:1991-1998.
32. Adamo A, Barrero MJ and Izpisua Belmonte JC. LSD1 and pluripotency: a new player in the network. Cell Cycle. 2011; 10:3215-3216.
33. Han X, Gui B, Xiong C, Zhao L, Liang J, Sun L, Yang X, Yu W, Si W, Yan R, Yi X, Zhang D, Li W, Li L, Yang J, Wang Y, et al. Destabilizing LSD1 by Jade-2 promotes neurogenesis: an antibraking system in neural development. Molecular cell. 2014; 55:482-494.
34. Amente S, Bertoni A, Morano A, Lania L, Avvedimento EV and Majello B. LSD1-mediated demethylation of histone H3 lysine 4 triggers Myc-induced transcription. Oncogene. 2010; 29:3691-3702.
35. Lutz W, Stohr M, Schurmann J, Wenel A, Lohr A, Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of a-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene. 1996; 13:803-812.
36. Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, Lunec J and Tweddle DA. p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer research. 2010; 70:1377-1388.
37. Lim S, Janzer A, Becker A, Zimmer A, Schule R, Buettner R, Kirfel J. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancer and a biomarker predicting aggressive biology. Carcinogenesis. 2010; 31:512-520.
38. Muller I, Larsson K, Frenzel A, Oliynyk G, Zirath H, Prochownik EV, Westwood NJ and Henriksson MA. Targeting of the MYCN protein with small molecule c-MYC inhibitors. PloS one. 2014; 9:e97285.
39. Westermark UK, Wilhelm M, Frenzel A, Henriksson MA. The MYCN oncogene and differentiation in neuroblastoma. Seminars in Cancer Biology. 2011; 4:256-266.
40. Zibetti C, Adamo A, Binda C, Forneris F, Toffolo E, Verpelli C, Ginelli E, Mattevi A, Sala C, Battaglioli E. Alternative splicing of the histone demethylase LSD1/KDM1 contributes to the modulation of neurite morphogenesis in the mammalian nervous system. J Neurosci. 2010; Feb 17;30(7):2521-32
41. Laurent B, Ruitu L, Murn J, Hempel K, Ferrao R, Xiang Y, Liu S, Garcia BA, Wu H, Wu F, Steen H, Shi Y. Mol Cell. 2015; 19: 957-970. Feb 11.
42. Amente S, Gargano B, Diolaiti D, Della Valle G, Lania L and Majello B. p14ARF interacts with N-Myc and inhibits its transcriptional activity. FEBS letters. 2007; 58:821-825.
43. Arrington AK, Davydova J, Vickers SM, Yamamoto M. Anti-ERBB2 sh-RNA suppress both cell growth and tumor growth in ERBB2-overexpression upper gastrointestinal adenocarcinomas. J Gastrointest Surg. 2009; 13:1754-1761.